TY - JOUR
T1 - Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice
AU - Amran, Muhammad Yunus
AU - Fujii, Jun
AU - Kolling, Glynis L.
AU - Villanueva, Sharon Y.A.M.
AU - Kainuma, Mosaburo
AU - Kobayashi, Hideyuki
AU - Kameyama, Hideko
AU - Yoshida, Shin ichi
N1 - Funding Information:
This study was supported, in part, by funds from the 851114300001 Health and Labor Sciences Research Grants for Research on global health issues from the Ministry of Health, Labor and Welfare, Japan and grant 23500479 and 22590256 from the Ministry of Education, Science, Culture and Sports of Japan . The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PY - 2013/12
Y1 - 2013/12
N2 - Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C invivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 invitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.
AB - Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C invivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 invitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.
UR - http://www.scopus.com/inward/record.url?scp=84886239396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886239396&partnerID=8YFLogxK
U2 - 10.1016/j.micpath.2013.09.008
DO - 10.1016/j.micpath.2013.09.008
M3 - Article
C2 - 24120399
AN - SCOPUS:84886239396
SN - 0882-4010
VL - 65
SP - 57
EP - 62
JO - Microbial Pathogenesis
JF - Microbial Pathogenesis
ER -
